Trial Profile
A Phase 2A, Prospective, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults Following Ischemic Stroke
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Cenplacel L (Primary)
- Indications Stroke
- Focus Adverse reactions; Therapeutic Use
- Sponsors Celularity
- 14 Jul 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
- 25 Jun 2014 New trial record